Structure-affinity relationships of adenosine A2B receptor ligands

Medicinal Research Reviews

Volumn 26, Issue 5, 2006, Pages 667-698

  Beukers, Margot W ^a   Meurs, Illiana ^a   Ijzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adenosine A2B receptor; Agonists; Antagonists; Structure affinity relationships

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; [8 [1 (3 PHENYL 1,2,4 OXADIAZOL 5 YL)METHYL] 1H PYRAZOL 4 YL] 1,3 DIPROPYL 1H PURINE 2,6(3H,7H) DIONE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; CMB 6446; CVT 5440; ENPROFYLLINE; LUF 5451; LUF 5452; LUF 5475; LUF 5833; LUF 5834; LUF 5835; LUF 5844; LUF 5845; MRS 1177; MRS 1186; MRS 1204; MRS 1706; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; OSIP 339391; PSB 1115; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; LIGANDS; RECEPTOR, ADENOSINE A2B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33747167896     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20069     Document Type: Review

References (72)

1. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch Pharmacol 2000;362:364-374.
2. Klotz KN. Adenosine receptors and their ligands. Naunyn-Schmiedeberg's Arch Pharmacol 2000;362:382-391.
3. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-552.
4. 2B adenosine receptors. Curr Top Med Chem 2003;3:427-443.
5. Sands WA, Palmer TM. Adenosine receptors and the control of endothelial cell function in inflammatory disease. Immunol Lett 2005;101:1-11.
6. Livingston M, Heaney LG, Ennis M. Adenosine, inflammation and asthma-A review. Inflamm Res 2004;53:171-178.
7. 2B adenosine receptor in NIH 3T3 fibroblasts. Biochem Pharmacol 1994;47:801-814.
8. 2B adenosine receptors. Drug Dev Res 1999;47:45-53.
9. 2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 2002;45:2131-2138.
10. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedebergs Arch Pharmacol 1998;357:1-9.
11. Daly JW, Jacobson KA. Adenosine receptors: Selective agonists and antagonists. In: Belardinelli L, Pelleg A, editors. Adenosine and adenine nucleotides: From molecular biology to integrative physiology. Boston: Kluwer; 1995. pp 157-166.
12. 3 adenosine receptor. Mol Pharmacol 1994;45:1101-1111.
13. Robeva AS, Woodard RL, Jin XW, Gao ZH, Bhattacharya S, Taylor HE, Rosin DL, Linden J. Molecular characterization of recombinant human adenosine receptors. Drug Dev Res 1996;39:243-252.
14. 2B adenosine receptors: Radioligand binding, Western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol 1999;56:705-713.
15. 2B adenosine receptors. Biochem Pharmacol 2001;61:657-663.
16. 2B receptor. Mol Pharmacol 1997;52:846-860.
17. 2B adenosine receptor antagonist, inhibits degranulation of cultured human but not murine mast cells. J Allergy Clin Immunol 2001;107:S922.
18. Rall TW. The xanthines. In: Goodman L, Gilman A, editors. The pharmacological basis of therapeutics. 6th edn. New York: MacMillan; 1980. pp 592-607.
19. 2B4) cells. Br J Pharmacol 1996;119:1286-1290.
20. 2B receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995;96:1979-1986.
21. 2-adenosine receptors. Biochem Pharmacol 1988;37:655-664.
22. 2B adenosine receptors. Drug Des Discov 1999;16:217-226.
23. 2B adenosine receptors. J Med Chem 2000;43:1165-1172.
24. 2B adenosine receptor antagonist for the potential treatment of asthma. Bioorg Med Chem Lett 2005;15:609-612.
25. 2B adenosine receptor antagonists. J Med Chem 2004;47:1434-1447.
26. 2B adenosine receptor antagonists. Bioorg Med Chem Lett 2006;16:302-306.
27. 2B-selective adenosine receptor antagonists. J Med Chem 2002;45:1500-1510.
28. Daly JW. Analogs of caffeine and theophylline: activity as antagonists at adenosine receptors. In: Imai S, Nakazawa M. editors. Role of adenosine and adenine nucleotides in the biological system. New York: Elsevier Science Publishers; 1991. 119p.
29. Müller CE, Shi D, Manning M Jr, Daly JW. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: Structure-activity relationships at adenosine receptors. J Med Chem 1993;36:3341-3349.
30. 2 receptor subtypes. Mol Pharmacol 1993;43:909-914.
31. 3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 1993;44:524-532.
32. Yan L, Müller CE. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: Toward the development of sulfonic acid prodrugs with peroral bioavailability. J Med Chem 2004;47:1031-1043.
33. 2B. Eur J Med Chem 2004;39:879-887.
34. 2B adenosine receptor antagonists. WO patent 2005/042534.
35. 3 receptor subtype. J Med Chem 1996;39:4142-4148.
36. 3 receptor subtypes. J Med Chem 1998;41:2835-2845.
37. 2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity. Drug Dev Res 1999;48:95-103.
38. Suzuki F, Koike N, Shimada J, Kitamura S, Ichikawa S, Nakamura J, Shiozaki S. Depression remedy. WO patent 1995/07282.
39. 3 adenosine receptors in human tumor cell lines. Curr Med Chem 2005;12:1319-1329.
40. 3 adenosine receptor antagonists. J Med Chem 2002;45:770-780.
41. 2B adenosine receptor antagonists. Drug Dev Res 2001;53:225-235.
42. 2B adenosine receptor subtypes: A molecular modeling investigation. J Med Chem 2003;46:4287-4296.
43. 3 receptor antagonist with therapeutic potential. Bioorg Med Chem Lett 2005;15:3081-3085.
44. 3 receptor antagonists. Curr Top Med Chem 2004;4:863-870.
45. Bruns RF. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem Pharmacol 1981;30:325-333.
46. 1 adenosine receptor. J Med Chem 1991;34:2877-2882.
47. Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G. New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 1998;6:523-533.
48. 2B receptor. J Med Chem 2001;44:170-179.
49. 2B adenosine receptor antagonists. US patent 2004/0209899.
50. Daly JW, Padgett WL, Eger K. 7-Deaza-9-phenyladenines. A new class of adenosine receptor antagonists. Biochem Pharmacol 1988;37:3749-3753.
51. 1 selective adenosine receptor antagonists. J Med Chem 1990;33:2822-2828.
52. 2B selective antagonist compounds, their synthesis and use. US patent 2003/0229067.
53. 2B receptors. Biochem Pharmacol 2004;68:305-312.
54. Webb TR, Melman N, Lvovskiy D, Ji XD, Jacobson KA. The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg Med Chem Lett 2000;10:31-34.
55. 2B receptors. Bioorg Med Chem 2003;11:77-85.
56. Harada H, Asano O, Miyazawa S, Ueda M, Yasuda M, Yasuda N. 2-Aminopyridine compounds and use thereof as drugs. US patent 2004/0006082.
57. 2B adenosine receptor antagonists. WO patent 2005/040155.
58. 2B receptor for 2-(1-Hexynyl)adenosine. Mol Pharmacol 2000;58:1349-1356.
59. 3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 1993;44:524-532.
60. 2B adenosine receptors. Bioorg Med Chem Lett 2004;14:3607-3610.
61. 3H]MRE 2029-F20. Mol Pharmacol 2005;67:2137-2147.
62. Bruns RF. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol 1980;58:673-691.
63. 2B receptor: A search for potent agonists. Nucleos Nucleot 1998;17:969-985.
64. 2B adenosine receptor agonists: Synthesis and biological evaluation of 2-phenylhydroxypropynyl adenosine and NECA derivatives. Nucleosides Nucleotides Nucleic Acids 2004;23:471-481.
65. 2B receptors. Drug Dev Res 2000;49:85-93.
66. Cristalli G, Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN. Characterization of potent ligands at human recombinant adenosine receptors. Drug Dev Res 1998;45:176-181.
67. Gao ZG, Mamedova LK, Chen P, Jacobson KA. 2-Substituted adenosine derivatives: Affinity and efficacy at four subtypes of human adenosine receptors. Biochem Pharmacol 2004;68:1985-1993.
68. Rosentreter U, Henning R, Bauser M, Kraemer T, Vaupel A, Huebsch W, Dembowsky K, Salcher-Schraufstaetter O, Stasch J-P, Krahn T, Perzborn E. Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof. WO patent 2001/0125210.
69. Rosentreter U, Kraemer T, Shimada M, Huebsch W, Diedrichs N, Krahn T, Henninger K, Stasch J-P. Substituted 2-thio-3,5-dicyano-4-phenyl-6- aminopyridines and their use as adenosine receptor-selective ligands. WO patent 2003/03008384.
70. Rosentreter U, Kramer T, Shimada M, Hubsch W, Diedrichs N, Krahn T, Henninger K, Stasch J-P. Substituted 2-thio-3,5-dicyano-4-phenyl-6- aminopyridines and their use as adenosine receptor-selective ligands. US patent 2004/0176417.
71. 2B receptor with an improved selectivity profile compared to the reference agonist N- ethylcarboxamidoadenosine. J Med Chem 2004;47:3707-3709.
72. 1 receptor. J Med Chem 2005;48:2045-2053.